More articles about: Rogel Cancer Center

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. 

A study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.

The Stomp Out Sarcoma 5K joins patients, survivors, care providers, and loved ones to raise funds and awareness for sarcoma research at the U-M Rogel Cancer Center.

When treating for localized prostate cancer, surgery and radiation are usually what people hear about. However, there are other treatments that could be options under a heading of focal therapy. Dr. Andrew Wood, a urologic oncologist with U-M Health Rogel Cancer Center’s Weiser Center for Prostate Cancer talks about these options and which patients could benefit from them.

As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a recent study sheds light on whether patients are opting for it.

Brain and spinal cord tumors account for one in four childhood cancers. Although 75% of children survive for at least five years after being diagnosed, many patients have recurrent tumors that cannot be cured. Andrea Franson discusses current therapies for pediatric brain tumors, how viruses can be used to target tumor cells and the new phase 1 trial that started in May 2025.

University of Michigan Health Rogel Cancer Center scientists identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy for patients with aggressive subtypes of prostate cancer.

The University of Michigan team identified herpesvirus saimiri, which infects the T cells of squirrel monkeys, as a source of proteins that activate pathways in T cells that are needed to promote T cell survival.

University of Michigan researchers have identified that the balance between two proteins—STAT3 and STAT5—is important for making tumors vulnerable to immune checkpoint therapy, and targeting STAT3 degradation is a potential novel cancer immunotherapy strategy.

Tommy Schomaker received his heart transplant in elementary school at University of Michigan Health C.S. Mott Children's Hospital as a part of ongoing cardiology care he was receiving at Mott. As Tommy graduates from Michigan State University with a degree in nursing, he is working as a Nursing Assistant in Mott on the floor he was treated on.

Michigan Medicine radiation oncology staff help grant wishes and spread joy to pediatric cancer patients at C.S. Mott Children's Hospital.

U-M researchers have discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human and mouse models.

TODAY show star Jill Martin aims to help improve health care for all women through the Women's Health Luncheon.

U-M football fans Jim and Connie Achtenberg are turning their experience with glioblastoma into hope by funding research at Rogel Cancer Center.

Mary Vandewiele's commitment to integrative oncology training programs is a powerful example of how philanthropy advances patient care.